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Summary
Coumarin oral anticoagulant drugs have proven to be effective
for the prevention of thromboembolic events.World-wide,war-
farin is the most prescribed drug. In Europe,acenocoumarol and
phenprocoumon are also administered.Yet it has been proven
that variant alleles of the VKORC1 and CYP2C9 genotypes in-
fluence the pharmacokinetics and pharmacodynamics of these
drugs. The combination of these two variant genotypes is a
major cause of the inter-individual differences in coumarin anti-
coagulant drug dosage. Individuals who test positive for both
variant genotypes are at increased risk of major bleeding.The
impact of the CYP2C9 andVKORC1 genotype is most significant
during the initial period of coumarin anticoagulant therapy.The
effect ofVKORC1 allelic variants is relatively similar for all three
Keywords
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macodynamics
VKAs.The CYP2C9 polymorphism is associated with delayed
stabilisation for coumarin anticoagulants.The effects of CYP2C9
polymorphisms on the pharmacokinetics and anticoagulant re-
sponse are least pronounced in the case of phenprocoumon. In
the long term, patients using phenprocoumon have more often
international normalised ratio (INR) values in the therapeutic
range, requiring fewer monitoring visits. This leads us to con-
clude that in the absence of pharmacogenetic testing, phenpro-
coumon seems preferable for use in long-term therapeutic anti-
coagulation. Pharmacogenetic testing before initiating coumarin
oral anticoagulants may add to the safety of all coumarin antico-
agulants especially in the elderly receiving multiple drugs.
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Introduction
Coumarin anticoagulants, also called vitamin K antagonists
(VKAs), are effective in the prevention of venous and arterial
thromboembolism (1). VKAs suppress the regeneration of the
reduced form of vitamin K by inhibiting vitamin K epoxide re-
ductase. The vitamin K cycle regenerates reduced vitamin K1
from its epoxide.
.
Reduced vitamin K is a cofactor for post-trans-
lational gamma-carboxylation of glutamic acid residues on sev-
eral proteins for normal haemostasis. This results in negatively
charged gamma-carboxyglutamateson factors II, VII, IX, and X,
which bind to calcium cations and then to platelet phospholipid
membranes. Gamma-carboxylation is also required for the de-
velopment of other tissues. VKAs also inhibit the gamma-car-
boxylation of anticoagulant proteins C, S, Z, and osteocalcin.
VKAs inhibition of clotting factor activity is their main phar-
macologic effect. This is responsible for VKAs ability to inhibit
clot formation.
The major side effect of VKAs is major bleeding, with re-
ported incidences of 1.5 to 5.0 per 100 patient-years (2, 3). The
incidence of both bleeding and thromboembolic events increases
sharply with advanced age. The risk of over- and under-coagu-
lation in patients taking VKAs is associated with drug-VKAs in-
teractions, food-VKAs interactions, and disease-VKAs interac-
tions. Alcohol consumption, liver disease, and other unknown
factors also influence optimal daily dosages. Other inter-individ-
ual variations that affect predicting optimal daily dosages in-
clude pharmacogenetic predisposition, age and patient obesity,
which corresponds to the amount of coumarin anticoagulants
required for initiation of therapy (4–6). This explains why oral
anticoagulants have a small therapeutic window, and the stability
of anticoagulant therapy can be easily disturbed.
Both safety (primarily risk of bleeding) and effectiveness of
VKAs therapy relates to blood international normalised ratio
(INR) values (7). Monitoring of INR and dose adjustments of
coumarin anticoagulants are frequently required. Futhermore,
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pharmacogenetics, the field of research describing the influence
of variations of DNA characteristics on drug response, plays an
important role in the safety and effectiveness of VKAs.
Warfarin is the VKAs drug of choice in most countries. Yet
acenocoumarol and phenprocoumon are used in many European
countries, including The Netherlands and Germany. Several re-
views and research papers on the pharmacogenetic influences of
warfarin are available (8, 9). Comparatively systematic informa-
tion on the pharmacogenetic influences of acenocoumarol and
phenprocoumon is scarce. In this review, we focus on the phar-
macogenetics of phenprocoumon and acenocoumarol, compar-
ing these drugs with the pharmacogenetics of warfarin. We also
explored these drugs’ relevance to therapeutic choices.
We performed the literature search in EMBASE and Medline
(PUBMED) from 1995 to June 2008. We included studies with
original data on pharmacogenetics of phenprocoumon and ace-
nocoumarol. Data from warfarin reviews and additional relevant
papers not included in the cited reviews were also included.
Search words and terms included: pharmacogenetics and/or
pharmacogenomics; acenocoumarol; phenprocoumon;
CYP2C9 and/or genotype and /or polymorphism; VKORC1;
warfarin and review; and coumarin anticoagulants.
Cytochrome P450 2C9 andVKORC1 and other
genetic variants
Cytochrome P450 (CYP) is a group of hepatic microsomal
enzymes that act as monooxygenases of endobiotics (steroid hor-
mones, fatty acids derivates, and vitamins) and xenobiotics
(drugs, pollutants, and carcinogens). The abbreviation CYP, fol-
lowed by a number, a capital letter and another number (e.g.
CYP2D6, CYP3A4, CYP2C9), designates an individual enzyme
from this group of monooxygenases. Cytochromes transform li-
pophilic drugs into more hydrophilic metabolites which facili-
tates further elimination and renal excretion.
The gene CYP2C9 encodes the enzyme CYP2C9, of which
about 30 variant alleles have been described. The most fre-
quently occurring variant alleles in Caucasians are CYP2C9*2
(CGT>TGT in exon 3) and CYP2C9*3 (ATT>CTT in exon 7)
(10).
These factors lead CYP2C9 to play a role in the metabolism of:
– Coumarin anticoagulant drugs (warfarin, acenocoumarol,
phenprocoumon)
– Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. diclo-
fenac, ibuprofen, lornoxicam, celecoxib, flurbiprofen, na-
proxen)
– Sulfonylureas (e.g. tolbutamide, glipizide)
– Phenytoin
Inhibitors of CYP2C9 include some SSRI type antidepressants
(e.g. fluoxetine, fluvoxamine), amiodarone, benzbromarone, co-
trimoxazol, cimetidine and antimycotic drugs (e.g. fluconazole,
miconazole, voriconazole). Inducers of CYP2C9 include rif-
ampicin and carbamazepin.
The gene VKORC1 encodes vitamin K-epoxide reductase
(VKORC1), of which several variant alleles have been de-
scribed. Coumarin anticoagulant derivatives targets VKORC1.
This complex recycles reduced vitamin K, which is essential for
the post-translational gamma-carboxylation of vitamin K–de-
pendent clotting factors II (prothrombin),VII, IX, and X, and of
proteins C, S and Z.
The impact of other enzymes polymorphisms, like GGCX
(gamma-glutamyl carboxylase), on coumarin anticoagulant dose
finding has been examined, but there are no significant results.
Warfarin
Warfarin is a racemate, with S-warfarin being three times as po-
tent as R-warfarin. The S-enantiomer in warfarin is predomi-
nantly responsible for the anticoagulant effect. When adminis-
tered orally, warfarin is completely absorbed and 99% is bound
to albumin in the plasma. The liver absorbs the free warfarin
where it exerts its anticoagulant effect and is metabolized by sev-
eral CYP-enzymes.
Yet from a clinical standpoint, R-warfarin is the most active
anticoagulant. This is because CYP2C9 metabolises S-warfarin
in the first-pass-effect very efficiently. CYP2C9 converts the
S-enantiomer to 6- and 7-hydroxy-warfarin, which is eventually
excreted in the bile. In comparison, CYP1A1, CYP1A2, and
CYP3A4 metabolize R-enantiomer into an inactive alcohol-
metabolite excreted in the urine.
Patients with either a CYP2C9*2 or CYP2C9*3 polymor-
phism have impaired metabolism of the more active enantiomer
S-warfarin when compared to patients who are homozygous for
the wild-type allele CYP2C9*1 (11). The unbound S-warfarin
clearance is about two- to three-fold lower in heterozygous car-
riers of the CYP2C9*3 allele and about 10-fold lower in homozy-
gous carriers (12).
In vivo, these two CYP2C9 SNPs have been associated with
increased responsiveness to warfarin (13). Aithal et al. (14) com-
pared controls requiring typical warfarin doses to patientswhose
therapeutic warfarin dose was 10.5 mg/week or less. They found
that patients requiring low doses of warfarin were more prone to
a supratherapeutic INR at the time of warfarin induction; were al-
most four times more prone to bleed; and were six times more
likely to have the CYP2C9*2 or CYP2C9*3 SNPs. Others found
that CYP2C9*3 decreased the selectivity of CYP2C9 for S-war-
farin and that residue 359, the mutated amino acid, was a com-
ponent of the warfarin-binding site.
Patients with one or two of these SNPs havereduced warfarin
requirements and an elevated risk of an adverse event by initial
warfarin therapy. The CYP2C9 SNPs are associated with a two-
to three-fold increasedrisk of bleeding during warfarin induction
(15). This observation suggests that pharmacogenetics-based
warfarin therapy will mainly affect the initial warfarin dosage(s).
However, because a CYP2C9 polymorphism is also associated
with a decreased chance to achieve stable anticoagulation (16), it
is possible that genotype-steered dosing can also play a role dur-
ing later stages of warfarin therapy.
Recently CYP4F2 genetic variants were associated with a
clinically relevant effect on warfarin requirement in the Cau-
casian population (17). Data from other ethnic groups and the
role CYP4F2 in acenocoumarol and phenprocoumon dose
requirement are lacking.
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Several genetic variations of the VKORC1 gene have been
found to influence sensitivity to warfarin (18, 19). Four different
heterozygous mutations in the VKORC1 gene were found in in-
dividuals with warfarin resistance. Rieder et al. (18) investigated
the genetic basis of the broad variation among patients in re-
sponse to warfarin therapy. They determined the VKORC1 ha-
plotype frequencies in African-American, European-American
and Asian-American populations, and they found VKORC1
mRNA expression in human liver samples. They found 28
VKORC1 SNPs in the primary population. Rieder et al. ident-
ified 10 common (>5%) noncoding VKORC1 single-nucleotide
polymorphisms (SNPs) and inferred five major haplotypes,
from which a low-dose haplotype group (A) and a high-dose ha-
plotype group (B) were derived.
Initial variability in the INR response is more strongly as-
sociated with VKORC1 than with CYP2C9 (20). The mean
maintenance dosages of warfarin differs significantly among the
three haplotype group combinations, at approximately 2.7 mg/
day for A/A, 4.9 mg/day for A/B, and 6.2 mg/day for B/B.
VKORC1 haplotype groups A and B explains approximately
25% of the variance in warfarin dose. Moreover, one single nu-
cleotide polymorphism, such as C1173T in intron 1, appears to
be as informative about coumarin anticoagulant sensitivity as all
the five major haplotypes, which represents 96% to 99% of the
total haplotypes. Asian-Americans have a higher proportion of
group A haplotypes, and African-Americans have a higher pro-
portion of group B haplotypes. Wadelius et al. (21) finds that
VKORC1 SNPs covaried significantly with warfarin dose,
which explains 30% of dose variations (22). Cytochrome P450
2C9 (CYP2C9) explains 12% of variance in warfarin dose (23).
The VKORC1 C1173 polymorphism is in strong disequilibrium
with VKORC1 promotor 1639. In Europeans, guanine (G) is ex-
pressed. In some other ethnic groups, adenine(A) is more com-
mon. A heterozygous or homozygous adenine (A) significantly
reduces VKOR expression compared with G / G. The VKORC1
variation p.Trp59Arg (24) and Asp36Tyr (25) have been de-
scribed to explain coumarin resistance.
Incorrect dosage, especially during the initial phase of treat-
ment, carries a high risk for either severe bleeding or failure to
prevent thromboembolism. Genotype-based dose predictions
may enable personalized drug treatment from the start of warfa-
rin therapy (26).
Acenocoumarol
Like S-warfarin, S-acenocoumarol is more potent than R-aceno-
coumarol and is metabolized by CYP2C9 (27–30). CYP1A2,
3A4, 2C9 and 2C19 metabolize R-acenocoumarol.An important
pharmacokinetic difference between warfarin and acenocouma-
rol is that S- and R-warfarin have half-lives of approximately 32
and 43 hours, while S- and R-acenocoumarol have half lives of 2
and 8 hours. As a result of slower elimination of the S-enanti-
omer, R-acenocoumarol is largely responsible for the overall
anticoagulant response. Furthermore, R-acenocoumarol is clini-
Figure 1:The influence of
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cally the more important enantiomer because of the very short
half-life of S-acenocoumarol (31).
Patients with a CYP2C9 variant allele have a higher risk of
early acenocoumarol overanticoagulation (32, 33). Patients with
the CYP2C9*3, but not the CYP2C9*2 variant, are known to
require a lower maintenance dose of racemic acenocoumarol
(34–37). The S-acenocoumarol clearance in a heterozygous car-
rier of the CYP2C9*3 allele is more than 15-fold lower than in
wild-type subjects. This difference between CYP2C9*2 and *3
discerns acenocoumarol from warfarin.The S-acenocoumarol
plasma half-life is prolonged in the CYP2C9*1/*3 genotypes.
The effect is that S-acenocoumarol pharmacokinetics is de-
pendent on the CYP2C9 genotype. Specifically, the presence of
the CYP2C9*3 allele impairs oral clearance of the coumarin
anticoagulants.The time needed to achieve stability is mainly as-
sociated with the CYP2C9 genotype.
The genotype VKORC1 modifies the effect of the CYP2C9
genotype on the anticoagulation status (38). In several studies,
the VKORC1 genotype, rather than by the CYP2C9 genotype,
explains a larger part of the dose requirement. Severe, over anti-
coagulation is mostly associated with the combination of variant
alleles of CYP2C9 and VKORC1 (39–41).
Phenprocoumon
Phenprocoumon seems preferable in poor metabolisers of cou-
marin anticoagulants (42). Phenprocoumon has a long half-life:
it is approximately 172 hours for the more potent S-phenprocou-
mon enantiomer, and approximately 156 hours for R-phenpro-
coumon. The S-enantiomer is predominantly responsible for the
anticoagulant effect in phenprocoumon. The S-7-hydroxylation
is the most important metabolising factor (43, 44).Yet the *2 and
*3 allele significantly compromises the S-7-hydroxylation in a
gene-dose-dependent manner. Phenprocoumon metabolism ap-
pears to be less influenced by the 2C9 genotypes when compared
with other coumarin anticoagulants (45, 46). S- and R- phenpro-
coumon are predominantly metabolised by CYP2C9 and 3A4
(Fig. 1).
The significant role of the non-polymorphic 3A4 in phenpro-
coumon metabolism makes it a possibly safer drug to use over
other coumarin anticoagulants. The oral clearance of S-aceno-
coumarol is more than 15-fold lower in a carrier of the heterozy-
gous *3 genotype compared with the *1 *1 genotype. The oral
clearance of S-phenprocoumon is only marginally reduced in
variant allele carriers (47). The clearance of R-phenprocoumon
is essentially unchanged. About 40% of an oral dose of phenpro-
coumon is excreted unchanged (48, 49), whereas warfarin and
acenocoumarol are almost completely metabolised (Table 1)
(50). Phenprocoumon therefore seems preferable in poor meta-
bolisers of coumarin anticoagulants.
Finally, like S-warfarin and S-acenocoumarol, both S- and
R-phenprocoumon inhibit vitamin K epoxide reductase (the
S-enantiomer being 2–5 times as potent as the R-enantiomer).
The effects of the CYP2C9 polymorphisms on the phar-
macokinetics and anticoagulant response are least pronounced
for phenprocoumon, yet the VKORC1 genotype can modify the
effect of the CYP2C9 genotype on phenprocoumon dose
requirements. Greater variability in dose requirement is ob-
served by theVKORC1 genotype than by the CYP2C9 genotype.
Schalekamp et al. showed that in patients without a VKORC1
variant allele, carriers of a CYP2C9 variant need dosages that are
nearly 30% lower than those for CYP2C9*1/*1 patients (51). In
patients with a VKORC1 variant allele, differences between car-
riers of a CYP2C9 variant and CYP2C9*1/*1 are statistically in-
significant, suggesting that differences between CYP2C9 geno-
types mainly apply to patients without a VKORC1 variant allele.
Carriers with a combination of CYP2C9 variant and VKORC1
variant alleles show a significant increase in the risk of severe
overanticoagulation, whereas delayed stabilization is mainly as-
sociated with the CYP2C9 genotype. Carriers of the *3 allele
have a higher risk of bleeding (52). From a clinical perspective,
the bleeding risk of patients using phenprocoumon should be
taken into consideration (53).
Patients using phenprocoumon have more stable INR values
than patients on acenocoumarol and require fewer monitoring vi-
sits (54, 55). Because of the long half-life time, overanticoagu-
lated patients using phenprocoumon are at greater risk of major
bleedings due to the prolonged period of overanticoagulation.
Coumarin anticoagulants and NSAIDs drug-drug
interactions
CYP2C9 metabolises several drugs (see above), especially some
NSAIDs, making a pharmacokinetic interaction with the couma-
rin anticoagulants conceivable (56–58). The effects of NSAIDs
are well documented. NSAIDs (excluding cyclooxygenase
[COX]2-selective NSAIDs) inhibit platelet aggregation which
increases the risk of bleeding (59). This pharmacodynamic inter-
action is not reflected by a change in the prothrombin time as
Table 1:The impact of pharmacogenetics on the different coumarin drugs. T ½ is the half-life time of a coumarin in the blood. The dose
variance is the impact of the genotype on the coumarin dose required to get INR values within target range. The administration of NSAIDs can delay
the metabolism of some coumarins.
Dose variance (%) NSAID
T ½ (hours) VKORC1 CYP2C9 Delayed metabolism
Warfarin 32–43 25 (14–36) 13 (4–21) 1.32 fold
Acenocoumarol 2–8 29 (21–36) 10 (5–14) 1.28 fold
Phenprocoumon 156–178 29 7 1.11 fold
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measured by the INR. Kohl et al. introduced a model to approach
the interaction of NSAIDs with coumarin anticoagulants based
on CYP2C9 and compared it with studies in vivo. They found an
increase in plasma concentrations of coumarin anticoagulants:
1.32 fold for racemic warfarin; 1.28 fold for racemic acenocou-
marol; 1.11 fold for racemic phenprocoumon. For S-warfarin the
increase is 1.58-fold; for S-phenprocoumon it was 1.13 fold.
In patients treated with acenocoumarol, the risk of overanti-
coagulation when using CYP2C9 metabolised NSAIDs was
modified by allelic variants of CYP2C9, especially CYP2C9*3.
This was not observed with phenprocoumon. Possibly there were
not enough patients included in this study for a firm conclusion.
Patients who have a variant CYP2C9 enzyme and use aceno-
coumarol are at greater risk of INR values above 4.9 when con-
comitant NSAIDs are used (60). Analysis of the variant groups
for NSAID users shows that there is no difference within the
wild-type subgroups, because these patients have the full capac-
ity for eliminating drugs. An increase in the measured INRs is
seen only in the subgroup of patients with CYP2C9 variants type
*2 or *3 who also use NSAIDs. The capacity of the CYP2C9
variant polymorphisms to hydroxylate substrate drugs is dimin-
ished, and the administration of two substrate drugs may have
pharmacokinetic effects on the elimination on one or both drugs.
Masche et al. investigated the effect of the co-administration
of the NSAID lornoxicam on S- and R- phenprocoumon and
found that it mainly alters the pharmacokinetics of S-phenpro-
coumon (61).
Conclusion
Knowing about the presence of both CYP2C9 and VKORC1 in
the patient’s genotype broadens our insight into the activity of the
different coumarin anticoagulants in the individual patient con-
tributing to a safer pharmacotherapy (62–66).
The effect of VKORC1 allelic variants is relatively similar
for all three VKAs and explains 25% of the variance of the re-
sponse to coumarin anticoagulant therapy. The effect of the
CYP2C9*2 and *3 polymorphisms is most prominent for warfa-
rin. For acenocoumarol, only CYP2C9*3 has an effect. For phen-
procoumon, we observe a marginal effect of the CYP2C9 poly-
morphisms, which is probably limited to patients without a
VKORC1 variant allele.
The combination of variant VKORC1 and CYP2C9 alleles
explains a major part of the inter-individual differences in VKAs
dosages (67). The combination of variant VKORC1 and
CYP2C9 alleles increases the risk of major bleedings. The im-
pact of the combination of the polymorphisms is the greatest in
the initial weeks of starting coumarin anticoagulant therapy. De-
layed stabilisation is associated with having a CYP2C9 polymor-
phism. The CYP4F2 genetic variant alters the required warfarin
dose, data for acenocoumarol and phenprocoumon are lacking.
Race-based differences in warfarin maintenance dose seems
mainly dependent on the linked VKORC1 variants. Although
speculative, one can expect the same pattern for acenocoumarol
and phenprocoumon.
From a clinical perspective, phenprocoumon seems prefer-
able for therapeutic anticoagulation in the absence of pharmaco-
genetic testing. Phenprocoumon therapy shows the least risk of
delayed destabilisation compared to warfarin or acenocoumarol.
The effects of CYP2C9 polymorphisms on the pharmacokinetics
and anticoagulant response are least pronounced in the case of
phenprocoumon. Patients on phenprocoumon have INR values
more often in the therapeutic window and require less control
than patients on acenocoumarol. The drug-drug pharmacoki-
netic interactions with NSAIDs are the least pronounced for
phenprocoumon.
Pharmacogenetic testing may add to the safety of coumarin
anticoagulant therapy. Pharmacoeconomic evaluations of phar-
macogenetic testing suggest this is cost-effective for acenocou-
marol and warfarin (68, 69).
What is known about this topic?
− Coumarin anticoagulants are metabolized predominantly
by CYP2C9. Their target on the enzyme vitamin K epox-
idase is VKORC1.
− CYP2C9 and VKORC1 genetic variants are associated
with variability in coumarin anticoagulant dose require-
ment, overanticoagulation, stabilization and bleeding risk.
What does this paper add?
− In this paper a comparison is made between the role of
CYP2C9 and VKORC1 genetic variants for the coumarin
anticoagulants warfarin, acenocoumarol and phenprocou-
mon.
− We conclude that the impact of genetic variants of
CYP2C9 and VKORC1 on warfarin, acenocoumarol and
phenprocoumon is quite different.
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